## Metalworking fluids and cancer mortality in a US autoworker cohort (1941–2015)<sup>1</sup>

by Sadie Costello, PhD,<sup>2</sup> Kevin Chen, MPH, Sally Picciotto, PhD, Liza Lutzker, MPH, Ellen Eisen, ScD

- 1. Appendix
- Correspondence to: Sadie Costello, PhD, Environmental Health Science, School of Public Health, University of California, Berkeley, 2121 Berkeley Way #5302, Berkeley, CA 94720-7360, USA. [E-mail: Sadie@berkeley.edu]

Table S1. International Classification of Diseases (ICD) codes used to define cases. Deaths prior to 1999 were defined with respect to the 9<sup>th</sup> revision. Deaths in or after 1999 were defined with respect to the 10<sup>th</sup>.

respect to the 10 <sup>th</sup> .		
Cause of death	ICD 9	ICD 10
All causes	_	_
All natural causes	001–799	A00–R99, U00–Z99
All cancers	140–239	C00–C99, D00–D49
Esophageal cancer	150	C15
Stomach cancer	151	C16
Intestinal cancer	152–153	C17–C18
Rectal cancer	154	C19–C21
Kidney cancer	189.0, 189.2	C64–C66
Bladder and urinary organ cancers	188, 189.3–189.9	C67–C68
Bile duct, liver, and gallbladder cancers	155–156	C22–C24
Pancreatic cancer	157	C25
Laryngeal cancer	161	C32
Lung cancer	162	C33–C34
Skin cancer	172–173	C43–C44, C46.0, C46.9
Prostate cancer	185	C61
Brain and nervous system cancers	191–192	C47, C70–C72
Leukemia	204–208	C91.0–C91.3, C91.5–
		C91.9, C92–C95
Breast cancer	174–175	C50
All nonmalignant respiratory	460-466, 470-478, 480-	A48.1, J00–J01, J02.8–
diseases	487, 490–495, 496–519	J02.9, J03.8–J03.9, J04–
		J06, J10–J18, J20–J22,
		J40–J46, J30–J33, J34.1–
		J34.8, J35–J39, J47,
		J60:J95, J98, R09.1
Chronic obstructive pulmonary	490–492, 496	J40–J44
disease	100 100	A 40 1 112 110
Pneumonia	480–486	A48.1, J12–J18

Cirrhosis and other chronic liver disease	571	K70, K73–K74, K76.0
All heart diseases	390–398, 402, 404, 410– 414, 420–429	I00–I09, I11–I13, I20–I22, I24–I25, I30–I38, I40, I42, I44–I52, I97.0–I97.1,
Ischemic heart disease	410–414	I97.8–I97.9, R00.1, R00.8 I20–I22, I24–I25, I51.3, I51.6
Rheumatic heart disease	390–398	I00–I09
Cerebrovascular disease	430–438	G45.0–G45.2, G45.4–
		G45.9, I60–I69
All external causes	E800–E848, E850–E888,	V00–V99, W00-W99,
	E929–E978, E980–E999	X00–X84, X85–X99,
		Y00–Y36, Y40–Y89

Table S2. Cox model estimates of the hazard ratio for selected cancer outcomes associated with exposure to straight metalworking fluids, controlling for other fluid types, calendar year, calendar year of hire, age, race, sex, and plant.

			Number of	HR	95% CI
			cases		
Laryngeal cance	er (73 cases)				
	0	mg/m <sup>3</sup> ·years	40	1.0	_
				0	
	> 0 to 0.5	mg/m <sup>3</sup> ·years	17	1.1	(0.59–2.37)
		0,		8	
	> 0.5	mg/m <sup>3</sup> ·years	16	0.8	(0.41–1.59)
	2 0.5	ing/in years	10	1	(0.41 1.57)
Lung concor (19	201 20222)			1	
Lung cancer (18	â		0(4	1.0	
	0	mg/m <sup>3</sup> ·years	964	1.0	_
		. 2		0	
	> 0 to 0.3	mg/m <sup>3</sup> ·years	309	1.0	(0.92 - 1.25)
				7	
	> 0.3 to 1.6	mg/m <sup>3</sup> ·years	309	0.9	(0.82 - 1.12)
				6	
	> 1.6	mg/m <sup>3</sup> ·years	309	0.9	(0.78 - 1.05)
	-	8 1		1	()
Esophageal can	cer (176 cases)			1	
Loophagear can	0	mg/m <sup>3</sup> ·years	83	1.0	
	0	ing/in years	85		—
		/ 3	21	0	(0,71,1,01)
	> 0 to 0.4	mg/m <sup>3</sup> ·years	31	1.1	(0.71 - 1.91)
		2		7	
	> 0.4 to 2.1	mg/m <sup>3</sup> ·years	32	1.1	(0.74 - 1.92)
				9	
	> 2.1	mg/m <sup>3</sup> ·years	30	1.1	(0.73 - 1.85)
				6	` '
				-	

Stomach cancer	Stomach cancer (192 cases)							
	0	mg/m <sup>3</sup> ·years	103	1.0 0	_			
	> 0 to 0.3	mg/m <sup>3</sup> ·years	30	0 1.1 6	(0.70–1.91)			
	> 0.3 to 2.9	mg/m <sup>3</sup> ·years	29	0.8 0	(0.49–1.32)			
	> 2.9	mg/m <sup>3</sup> ·years	30	0 1.8 6	(1.17–2.97)	*		
Colon cancer (4	07 cases)			0				
X	0	mg/m <sup>3</sup> ·years	211	1.0 0	_			
	> 0 to 0.5	mg/m <sup>3</sup> ·years	66	0.8 9	(0.64–1.23)			
	> 0.5 to 2.1	mg/m <sup>3</sup> ·years	65	0.9 3	(0.67–1.29)			
	> 2.1	mg/m <sup>3</sup> ·years	65	0.9 2	(0.68–1.25)			
Rectal cancer (8	3 cases)			Z				
(-	0	mg/m <sup>3</sup> ·years	44	1.0	_			
	> 0 to 1	mg/m <sup>3</sup> ·years	20	0.7	(0.40–1.51)			
	> 1	mg/m <sup>3</sup> ·years	19	8 0.8	(0.47–1.68)			
Bladder cancer (	(138 cases)			9				
Diadder cancer (	0	mg/m <sup>3</sup> ·years	73	1.0 0	_			
	> 0 to 0.3	mg/m <sup>3</sup> ·years	20	0.9 0	(0.51–1.61)			
	> 0.3 to 1.8	mg/m <sup>3</sup> ·years	22	0 0.6 5	(0.37–1.13)			
	> 1.8	mg/m <sup>3</sup> ·years	23	3 0.7 0	(0.42–1.16)			
Liver cancer (12	(3 cases)			0				
(1_	0	mg/m <sup>3</sup> ·years	55	1.0 0	_			
	> 0 to 0.5	mg/m <sup>3</sup> ·years	22	1.0 5	(0.58–1.89)			
	> 0.5 to 1.6	mg/m <sup>3</sup> ·years	23	1.9	(1.09–3.31)	*		
	> 1.6	mg/m <sup>3</sup> ·years	23	0 1.2	(0.72–2.13)			
Pancreatic cance	er (315 cases)			4				
	0	mg/m <sup>3</sup> ·years	154	1.0 0	_			

	> 0 to 0.3	mg/m <sup>3</sup> ·years	54	1.2	(0.87–1.81)	
	> 0.3 to 1.1	mg/m <sup>3</sup> ·years	53	5 1.1 7	(0.80–1.70)	
	> 1.1	mg/m <sup>3</sup> ·years	54	7 0.8 5	(0.60–1.21)	
Skin cancer (69	cases)			3		
Skill calleer (0)	0	mg/m <sup>3</sup> ·years	32	1.0 0	_	
	> 0 to 0.9	mg/m <sup>3</sup> ·years	18	1.1 7	(0.58–2.34)	
	> 0.9	mg/m <sup>3</sup> ·years	19	1.3 2	(0.67–2.58)	
Prostate cancer	(417 cases)					
	0	mg/m <sup>3</sup> ·years	192	1.0 0	_	
	> 0 to 0.5	mg/m <sup>3</sup> ·years	75	1.1 5	(0.84–1.57)	
	> 0.5 to 2	mg/m <sup>3</sup> ·years	75	1.1 1	(0.81–1.52)	
	> 2	mg/m <sup>3</sup> ·years	75	1.0 5	(0.78–1.41)	
Brain and nervo	us system cancers	s (128 cases)				
	0	mg/m <sup>3</sup> ·years	74	1.0 0	_	
	> 0 to 1	mg/m <sup>3</sup> ·years	27	0.6 1	(0.35–1.05)	•
	>1	mg/m <sup>3</sup> ·years	27	0.7 3	(0.44–1.22)	
Leukemia (200	cases)					
	0	mg/m <sup>3</sup> ·years	100	1.0 0	_	
	> 0 to 0.3	mg/m <sup>3</sup> ·years	34	1.0 9	(0.69–1.75)	
	> 0.3 to 2.3	mg/m <sup>3</sup> ·years	33	0.7 7	(0.48–1.23)	
	> 2.3	mg/m <sup>3</sup> ·years	33	0.9 4	(0.60–1.48)	
Breast cancer (7	6 cases)					
	0	mg/m <sup>3</sup> ·years	43	1.0 0	_	
	> 0 to 0.7	mg/m <sup>3</sup> ·years	16	1.3 4	(0.64–2.82)	
	> 0.7	mg/m <sup>3</sup> ·years	17	2.1 3	(1.04–4.39)	*

	Tace, sex, and pla		Number of cases	HR	95% CI
Laryngeal can	cer (73 cases)				
Lui jiigoui ouii	0 to 0.05	mg/m <sup>3</sup> ·years	18	1.0	_
				0	
	> 0.05 to 7.3	mg/m <sup>3</sup> ·years	28	0.7	(0.39–1.58)
				8	
	> 7.3	mg/m <sup>3</sup> ·years	27	0.8	(0.42 - 1.83)
•				7	
Lung cancer (	· · · · · · · · · · · · · · · · · · ·	. 2			
	0 to 0.05	mg/m <sup>3</sup> ·years	432	1.0	—
				0	
	> 0.05 to 3.3	mg/m <sup>3</sup> ·years	487	0.9	(0.84 - 1.12)
				7	
	> 3.3 to 11.2	mg/m <sup>3</sup> ·years	486	0.9	(0.77 - 1.04)
				0	
	> 11.2	mg/m <sup>3</sup> ·years	486	1.0	(0.85 - 1.17)
				0	. /
Esophageal ca	ncer (176 cases)				
1 0	0 to 0.05	mg/m <sup>3</sup> ·years	34	1.0	_
		6 ) 5	-	0	
	> 0.05 to 3.3	mg/m <sup>3</sup> ·years	46	1.0	(0.64–1.74)
	0.00 10 5.5	ing in yours	10	5	(0.01 1.71)
	> 3.3 to 10.8	mg/m <sup>3</sup> ·years	47	1.0	(0.62–1.74)
	5.5 10 10.0	ing/in years	• /	4	(0.02 1.71)
	> 10.8	mg/m <sup>3</sup> ·years	49	1.1	(0.68–2.04)
	- 10.0	ing/in years	12	8	(0.00 2.01)
Stomach cance	er(192 cases)			0	
	0 to 0.05	mg/m <sup>3</sup> ·years	58	1.0	_
	0 10 0.05	mg/m years	50	1.0 0	-
	> 0.05 to 4.2	mg/m <sup>3</sup> ·years	45	0.6	(0.42–1.07)
	- 0.03 10 4.2	mg/m years	<b>-</b> 1 <i>J</i>	0.0 7	(0.42 - 1.07)
	> 4.2 to 10	mg/m <sup>3</sup> ·years	44	1.0	$(0.66 \ 1.74)$
	< 4.2 to 10	mg/m <sup>*</sup> years	44		(0.66 - 1.74)
	> 10		15	7	(0, 12, 1, 10)
	> 10	mg/m <sup>3</sup> ·years	45	0.7	(0.42–1.18)
C 1				0	
Colon cancer		/ 3	00	1.0	
	0 to 0.05	mg/m <sup>3</sup> ·years	80	1.0	_
	0.07	, 2	100	0	
	> 0.05 to 3.5	mg/m <sup>3</sup> ·years	109	1.1	(0.83 - 1.57)
		-		4	
	> 3.5 to 12	mg/m <sup>3</sup> ·years	109	0.9	(0.69 - 1.35)

Table S3. Cox model estimates of the hazard ratio for selected cancer outcomes associated with exposure to soluble metalworking fluids, controlling for other fluid types, calendar year, calendar year of hire, age, race, sex, and plant.

	> 12	mg/m <sup>3</sup> ·years	109	0.9 4	(0.66–1.33)	
Rectal cancer (8	3 cases)					
	0 to 0.05	mg/m <sup>3</sup> ·years	20	1.0 0	_	
	> 0.05 to 4.6	mg/m <sup>3</sup> ·years	19	0.8 5	(0.41–1.76)	
	> 4.6 to 8.6	mg/m <sup>3</sup> ·years	23	2.1 8	(1.07–4.48)	*
	> 8.6	mg/m <sup>3</sup> ·years	21	0.8 6	(0.40–1.84)	
Bladder cancer	(138 cases)					
	0 to 0.05	mg/m <sup>3</sup> ·years	26	1.0 0	_	
	> 0.05 to 3.7	mg/m <sup>3</sup> ·years	37	1.1 0	(0.63–1.91)	
	> 3.7 to 11.1	mg/m <sup>3</sup> ·years	36	1.1 8	(0.67–2.07)	
	> 11.1	mg/m <sup>3</sup> ·years	39	1.1 3	(0.63–2.02)	
Liver cancer (12	23 cases)					
X	0 to $0.05$	mg/m <sup>3</sup> ·years	22	1.0 0	-	
	> 0.05 to 2.3	mg/m <sup>3</sup> ·years	34	1.2 9	(0.71–2.33)	
	> 2.3 to 9.2	mg/m <sup>3</sup> ·years	32	0.7 6	(0.41–1.40)	
	> 9.2	mg/m <sup>3</sup> ·years	35	0.9 3	(0.50–1.74)	
Pancreatic cance	er (315 cases)					
	$\dot{0}$ to $0.05$	mg/m <sup>3</sup> ·years	70	1.0 0	_	
	> 0.05 to $3.4$	mg/m <sup>3</sup> ·years	82	0.8 1	(0.56–1.16)	
	> 3.4 to $9.3$	mg/m <sup>3</sup> ·years	81	0.9 2	(0.63–1.34)	
	> 9.3	mg/m <sup>3</sup> ·years	82	$\begin{array}{c} 0.8 \\ 0 \end{array}$	(0.54–1.19)	
Skin cancer (69 cases)						
× ×	0 to $0.05$	mg/m <sup>3</sup> ·years	15	1.0 0	_	
	> 0.05 to 4.7	mg/m <sup>3</sup> ·years	26	1.6 9	(0.77–3.70)	
	> 4.7	mg/m <sup>3</sup> ·years	28	1.6 4	(0.71–3.80)	
-	· · · - ·					

Prostate cancer (417 cases)

	0 to 0.05	mg/m <sup>3</sup> ·years	68	1.0 0	_	
	> 0.05 to 5.1	mg/m <sup>3</sup> ·years	117	0 0.7 6	(0.54–1.05)	ŀ
	> 5.1 to 15.6	mg/m <sup>3</sup> ·years	116	0.7 9	(0.57–1.11)	
	> 15.6	mg/m <sup>3</sup> ·years	116	0.8 1	(0.57–1.14)	
Brain and nervo	ous system cancer	s (128 cases)		1		
	$\overline{0}$ to $\overline{0.05}$	mg/m <sup>3</sup> ·years	32	1.0	_	
	> 0.05 to 2.7	mg/m <sup>3</sup> ·years	32	1.5 1	(0.86–2.65)	
	> 2.7 to 9.2	mg/m <sup>3</sup> ·years	32	1 1.4 8	(0.82–2.68)	
	> 9.2	mg/m3·years	32	1.5	(0.82–2.90)	
Leukemia (200	(26202)			4		
Leukenna (200	0 to $0.05$	mg/m <sup>3</sup> ·years	48	1.0	_	
	> 0.05 to 3.3	mg/m <sup>3</sup> ·years	51	0 1.0 3	(0.65–1.64)	
	> 3.3 to 9.7	mg/m <sup>3</sup> ·years	50	5 1.0 9	(0.67–1.76)	
	> 9.7	mg/m <sup>3</sup> ·years	51	0.8	(0.53–1.45)	
Dreast correct (7	(			7		
Breast cancer (7	1000000000000000000000000000000000000	mg/m <sup>3</sup> ·years	36	1.0	_	
	> 0.05 to 2.9	mg/m <sup>3</sup> ·years	22	0 0.5	(0.30–1.14)	
	> 2.9	mg/m <sup>3</sup> ·years	18	9 0.5 6	(0.26–1.21)	

Table S4. Cox model estimates of the hazard ratio for selected cancer outcomes associated with exposure to synthetic metalworking fluids, controlling for other fluid types, calendar year, calendar year of hire, age, race, sex, and plant.

		Number of cases	HR	95% CI
Laryngeal cancer (73 cases)				
0	mg/m <sup>3</sup> ·years	54	1.0	_
> 0	mg/m <sup>3</sup> ·years	19	•	(0.67–2.78)
Lung cancer (1891 cases)				
0	mg/m <sup>3</sup> ·years	1374	1.0	_

	> 0 to 0.3	mg/m <sup>3</sup> ·years	173	0.9	(0.77–1.12)
	> 0.3 to 1.4	mg/m <sup>3</sup> ·years	172	3 1.0 7	(0.89–1.29)
	> 1.4	mg/m <sup>3</sup> ·years	172	7 1.0 0	(0.84–1.20)
Esophageal cano	cer (176 cases)				
	0	mg/m <sup>3</sup> ·years	126	1.0	_
	> 0 to 0.7	mg/m <sup>3</sup> ·years	25	0 1.1 3	(0.66–1.96)
	> 0.7	mg/m <sup>3</sup> ·years	25	1.3 9	(0.84–2.30)
Stomach cancer	(192 cases)				
	0	mg/m <sup>3</sup> ·years	149	1.0	_
	> 0 to 0.5	mg/m <sup>3</sup> ·years	22	0 1.0	(0.61–1.84)
		ing/in years		6	(0.01 1.01)
	> 0.5	mg/m <sup>3</sup> ·years	21	0.9	(0.53–1.56)
C 1 (4)	07			0	
Colon cancer (4	0 / cases)	mg/m <sup>3</sup> ·years	310	1.0	
	0	ing/in years	510	0	_
	> 0 to 0.4	mg/m <sup>3</sup> ·years	33	0.7 9	(0.52–1.21)
	> 0.4 to 1.7	mg/m <sup>3</sup> ·years	32	0.9 8	(0.65–1.50)
	> 1.7	mg/m <sup>3</sup> ·years	32	0.9 2	(0.62–1.38)
Rectal cancer (8	3 cases)			2	
× ×	0	mg/m <sup>3</sup> ·years	59	$\begin{array}{c} 1.0\\ 0 \end{array}$	—
	> 0 to 0.8	mg/m <sup>3</sup> ·years	12	1.4 9	(0.67–3.27)
	> 0.8	mg/m <sup>3</sup> ·years	12	1.6 4	(0.79–3.41)
Bladder cancer (	(138 cases)			т	
	0	mg/m <sup>3</sup> ·years	104	1.0 0	_
	> 0 to 0.5	mg/m <sup>3</sup> ·years	17	0.9 1	(0.49–1.70)
	> 0.5	mg/m <sup>3</sup> ·years	17	0.6 7	(0.37–1.21)
Liver cancer (12	23 cases)			,	
X	0	mg/m <sup>3</sup> ·years	89	1.0 0	_

$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			-			
$\begin{array}{c c c c c c c c } > 0.4 & mg/m^3 \cdot years & 17 & 0.8 & (0.48-1.63) \\ & & & & & & & & & & & & & & & & & & $		> 0 to 0.4	mg/m <sup>3</sup> ·years	17		(0.60–2.26)
Pancreatic cancer (315 cases)         0       mg/m <sup>3</sup> ·ycars       227       1.0       -         >0 to 0.3       mg/m <sup>3</sup> ·ycars       30       0.9       (0.62–1.55)         >0.3 to 0.9       mg/m <sup>3</sup> ·ycars       29       1.2       (0.80–2.00)         >0.9       mg/m <sup>3</sup> ·ycars       29       6       (0.56–1.34)         >0.9       mg/m <sup>3</sup> ·ycars       52       1.0       -         0       mg/m <sup>3</sup> ·ycars       52       1.0       -         0       mg/m <sup>3</sup> ·ycars       300       1.0       -         >0       mg/m <sup>3</sup> ·ycars       300       1.0       -         0       mg/m <sup>3</sup> ·ycars       300       1.0       -         0       mg/m <sup>3</sup> ·ycars       39       1.0       (0.67–1.50)         1       >0.5 to 2       mg/m <sup>3</sup> ·ycars       39       1.0       (0.67–1.50)         20 to 0.5       mg/m <sup>3</sup> ·ycars       39       1.1       (0.76–1.68)       3         21       mg/m <sup>3</sup> ·ycars       39       1.3       (0.89–1.89)       0         20 to 0.6       mg/m <sup>3</sup> ·ycars       17       1.5       (0.80–2.91)       2         20 to 0.6       mg/m <sup>3</sup> ·ycars       17		> 0.4	mg/m <sup>3</sup> ·years	17	0.8	(0.48–1.63)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$					8	
$\begin{array}{c cccccc} & & & & & & & & & & & & & & & & $	Pancreatic cance	er (315 cases)				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0	mg/m <sup>3</sup> ·years	227	1.0	_
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$					0	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		> 0 to 0.3	mg/m <sup>3</sup> ·years	30	0.9	(0.62 - 1.55)
$\begin{array}{c ccccc} & & & & & & & & & & & & & & & & &$					8	· · · ·
$\begin{array}{c ccccc} & & & & & & & & & & & & & & & & &$		> 0.3 to 0.9	mg/m <sup>3</sup> ·vears	29	1.2	(0.80 - 2.00)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$			8 5			(1 1 1 1)
Skin cancer (69 cases)       mg/m <sup>3</sup> ·years       52       1.0       - $\geq 0$ mg/m <sup>3</sup> ·years       17       0.6       (0.34–1.31)         Prostate cancer (417 cases)       0       mg/m <sup>3</sup> ·years       300       1.0       - $0$ mg/m <sup>3</sup> ·years       39       1.0       (0.67–1.50) $> 0$ to 0.5       mg/m <sup>3</sup> ·years       39       1.1       (0.67–1.50) $> 0$ to 0.5       mg/m <sup>3</sup> ·years       39       1.3       (0.89–1.89) $> 0.5$ to 2       mg/m <sup>3</sup> ·years       39       1.3       (0.89–1.89)         Brain and nervous system cancers (128 cases)       0       0       - $0$ mg/m <sup>3</sup> ·years       17       1.5       (0.80–2.91) $> 0.6$ mg/m <sup>3</sup> ·years       17       1.5       (0.80–2.91) $> 0.6$ mg/m <sup>3</sup> ·years       17       1.3       (0.75–2.47)         Leukemia (200 cases)       0       mg/m <sup>3</sup> ·years       142       1.0       - $0$ 0       mg/m <sup>3</sup> ·years       29       1.1       (0.67–1.82) $> 0.9$ mg/m <sup>3</sup> ·years       29       1.3       (0.86–2.19) $> 0.9$ mg/m <sup>3</sup> ·years       29 <td></td> <td>&gt; 0.9</td> <td><math>m\alpha/m^3 \cdot vears</math></td> <td>29</td> <td></td> <td>(0.56 - 1.34)</td>		> 0.9	$m\alpha/m^3 \cdot vears$	29		(0.56 - 1.34)
Skin cancer (69 cases)       0       mg/m <sup>3</sup> ·ycars       52       1.0 $-$ >0       mg/m <sup>3</sup> ·ycars       17       0.6       (0.34-1.31)         Prostate cancer (417 cases)       0       mg/m <sup>3</sup> ·ycars       300       1.0 $ 0$ mg/m <sup>3</sup> ·ycars       300       1.0 $ 0$ $0$ $0$ to 0.5       mg/m <sup>3</sup> ·ycars       39       1.1       (0.67-1.50) $0$ $0$ mg/m <sup>3</sup> ·ycars       39       1.1       (0.76-1.68) $0$ mg/m <sup>3</sup> ·ycars       39       1.3       (0.89-1.89)         Brain and nervous system cancers (128 cases)       0 $0$ $0$ $0$ $0$ mg/m <sup>3</sup> ·ycars       17       1.5       (0.80-2.91) $2$ $0$ $0$ $mg/m^3·ycars$ 17       1.3       (0.75-2.47) $6$ $0$ $mg/m^3·ycars$ 142 $1.0$ $ 0$ $0$ $mg/m^3·ycars$ 29 $1.3$ (0.86-2.19) $2$ $0$ $0$ $mg/m^3·ycars$ 29 $1.3$ (0.86-2.19) $0$ $0$		> 0.)	mg/m years	2)		(0.50 1.54)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Strin concor (60	2222			/	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Skill calleer (09	· ·		50	1.0	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		0	mg/m <sup>3</sup> ·years	52		_
7Prostate cancer (417 cases) $mg/m^3 \cdot years3001.0-0mg/m^3 \cdot years391.0(0.67-1.50)> 0 to 0.5mg/m^3 \cdot years391.1(0.76-1.68)> 2mg/m^3 \cdot years391.3(0.89-1.89)0mg/m^3 \cdot years391.3(0.89-1.89)0mg/m^3 \cdot years941.0-0mg/m^3 \cdot years171.5(0.80-2.91)> 0.6mg/m^3 \cdot years171.3(0.75-2.47)0mg/m^3 \cdot years171.3Leukemia (200 cases)-0mg/m^3 \cdot years1421.0-> 0 to 0.9mg/m^3 \cdot years291.1(0.67-1.82)> 0.9mg/m^3 \cdot years291.3(0.86-2.19)7Breast cancer (76 cases)10> 0mg/m^3 \cdot years601.0-> 0mg/m^3 \cdot years160.7(0.38-1.53)$			, 2	1 -		
Prostate cancer (417 cases)       0       mg/m <sup>3</sup> ·years       300       1.0 $ 0$ 0       0       mg/m <sup>3</sup> ·years       39       1.0       (0.67–1.50) $0$ 0.5 to 2       mg/m <sup>3</sup> ·years       39       1.1       (0.76–1.68) $0$ 2       mg/m <sup>3</sup> ·years       39       1.1       (0.76–1.68) $0$ mg/m <sup>3</sup> ·years       39       1.3       (0.89–1.89)         Brain and nervous system cancers (128 cases)       0       0       94       0 $0$ mg/m <sup>3</sup> ·years       94       1.0 $-$ 0 $0$ mg/m <sup>3</sup> ·years       17       1.5       (0.80–2.91)       2 $0$ 0       mg/m <sup>3</sup> ·years       17       1.3       (0.75–2.47) $0$ $0$ mg/m <sup>3</sup> ·years       142       1.0 $ 0$ $0$ $0$ $0$ $0$ $0$ Leukemia (200 cases) $0$ $0$ $1.1$ $(0.67–1.82)$ $1.1$ $0$ $0$ $0$ $0$ $0$ $1.3$ $(0.86–2.19)$ $0$ $0$ $0$ $0$ </td <td></td> <td>&gt; 0</td> <td>mg/m<sup>3</sup>·years</td> <td>17</td> <td></td> <td>(0.34 - 1.31)</td>		> 0	mg/m <sup>3</sup> ·years	17		(0.34 - 1.31)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$					7	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Prostate cancer (	(417 cases)				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		0	mg/m <sup>3</sup> ·years	300	1.0	_
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			0,		0	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		> 0 to 0.5	$mg/m^3 \cdot vears$	39	-	(0.67 - 1.50)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		0 00 010	ing in yours	0,7		(0.07 1.00)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		> 0.5 to 2	$ma/m^3$ .vears	30	-	(0.76, 1.68)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		> 0.5 to 2	mg/m years	59		(0.70 - 1.08)
000mg/m <sup>3</sup> ·years91.0 $-$ 0 $0$ mg/m <sup>3</sup> ·years17 $0$ mg/m <sup>3</sup> ·years17 $0$ mg/m <sup>3</sup> ·years17 $0$ mg/m <sup>3</sup> ·years17 $0$ mg/m <sup>3</sup> ·years142 $0$ mg/m <sup>3</sup> ·years142 $0$ mg/m <sup>3</sup> ·years29 $0$		× 0	/ 3	20		(0, 00, 1, 00)
Brain and nervous system cancers (128 cases) $mg/m^3 \cdot years$ 94 $1.0 - 0$ $0$ $mg/m^3 \cdot years$ 94 $1.0 - 0$ $0$ $mg/m^3 \cdot years$ 17 $1.5$ $(0.80-2.91)$ $2$ $0.6$ $mg/m^3 \cdot years$ 17 $1.3$ $(0.75-2.47)$ $0$ $mg/m^3 \cdot years$ 142 $1.0 - 0$ $0$ Leukemia (200 cases) $mg/m^3 \cdot years$ 29 $1.1$ $(0.67-1.82)$ $0$ $mg/m^3 \cdot years$ 29 $1.1$ $(0.86-2.19)$ $> 0.9$ $mg/m^3 \cdot years$ 29 $1.3$ $(0.86-2.19)$ $7$ $0$ $mg/m^3 \cdot years$ 29 $1.3$ $(0.86-2.19)$ $7$ $0$ $mg/m^3 \cdot years$ 60 $1.0 - 0$ $0$ $0$ $mg/m^3 \cdot years$ $60$ $1.0 - 0$ $0$ $0$ $0$ $mg/m^3 \cdot years$ $60$ $1.0 - 0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$		> 2	mg/m <sup>3</sup> ·years	39		(0.89 - 1.89)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			(1.0.0)		0	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Brain and nervo	-				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		0	mg/m <sup>3</sup> ·years	94	1.0	_
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					0	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		> 0 to 0.6	mg/m <sup>3</sup> ·years	17	1.5	(0.80 - 2.91)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						
Leukemia (200 cases)60mg/m <sup>3</sup> ·years1421.0> 0 to 0.9mg/m <sup>3</sup> ·years291.1> 0.9mg/m <sup>3</sup> ·years291.30mg/m <sup>3</sup> ·years291.30mg/m <sup>3</sup> ·years601.00mg/m <sup>3</sup> ·years6000mg/m <sup>3</sup> ·years16		> 0.6	mg/m <sup>3</sup> ·vears	17		(0.75 - 2.47)
Leukemia (200 cases) 0 $mg/m^{3} \cdot years$ 142 $> 0 \text{ to } 0.9$ $mg/m^{3} \cdot years$ 29 1.1 (0.67–1.82) 1 $> 0.9$ $mg/m^{3} \cdot years$ 29 1.3 (0.86–2.19) 7 Breast cancer (76 cases) 0 $mg/m^{3} \cdot years$ 60 1.0 – 0 $> 0$ $mg/m^{3} \cdot years$ 16			- <u>0</u> j •••••			(
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Leukemia (200 d	cases)			0	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			$ma/m^3 \cdot v_{abc}$	1/12	1.0	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		U	mg/m years	142		_
> 0.9mg/m <sup>3</sup> ·years291 1.3 7(0.86-2.19) 7Breast cancer (76 cases)0mg/m <sup>3</sup> ·years601.0-0mg/m <sup>3</sup> ·years600.70> 0mg/m <sup>3</sup> ·years160.7(0.38-1.53)				20		(0, (7, 1, 00))
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		> 0 to 0.9	mg/m <sup>3</sup> ·years	29	1.1	(0.6/-1.82)
Breast cancer (76 cases) 0 mg/m <sup>3</sup> ·years 60 $1.0 - 0$ > 0 mg/m <sup>3</sup> ·years 16 $0.7 (0.38-1.53)$						
Breast cancer (76 cases) 0 mg/m <sup>3</sup> ·years 60 $1.0 - 0$ > 0 mg/m <sup>3</sup> ·years 16 $0.7 (0.38-1.53)$		> 0.9	mg/m <sup>3</sup> ∙years	29		(0.86 - 2.19)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$					7	
>0 mg/m <sup>3</sup> ·years 16 $0$ 0.7 (0.38–1.53)	Breast cancer (7	6 cases)				
>0 mg/m <sup>3</sup> ·years 16 $0$ 0.7 (0.38–1.53)		0	mg/m <sup>3</sup> ·years	60	1.0	_
>0 mg/m <sup>3</sup> ·years 16 0.7 (0.38–1.53)						
		> 0	mg/m <sup>3</sup> ·vears	16		(0.38 - 1.53)
V		v				(0.00 1.00)
					0	